TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes mellitus~* Glycosylated haemoglobin (HbA1c) 7.0-9.0% (53-75 mmol/mol) (both inclusive)~* Treatment with daily GLP-1 receptor agonist at maximum dose according to local label (i.e. 1.8 mg once daily (OD) Victoza® (liraglutide) or 10 microgram twice daily (BID) Byetta® (exenatide)) or documented maximum tolerated dose (i.e. 1.2 mg OD Victoza® (liraglutide) or 5 microgram BID Byetta® (exenatide)) in combination with a stable daily dose of metformin (equal to or above 1500 mg or documented maximum tolerated dose) for 90 days or more prior to screening visit (Visit 1)~* BMI (body mass index) equal to or below 40 kg/m\^2~Exclusion Criteria:~* Any use of oral anti-diabetic drugs (OADs) (except for metformin, pioglitazone and sulphonylurea) for 90 days or less prior to screening visit (Visit 1)~* Use of any drug (except metformin,pioglitazone, sulphonylurea and GLP-1 receptor agonist) which in the Investigator's opinion could interfere with the blood glucose level (e.g. systemic corticosteroids)~* Treatment with any insulin regimen (short term treatment due to intercurrent illness including gestational diabetes is allowed at the discretion of the Investigator)~* Screening calcitonin equal to or above 50 ng/l~* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)~* Cardiovascular disorders defined as: congestive heart failure (New York Heart Association (NYHA) class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the past 52 weeks prior to screening visit (Visit 1) and/or planned coronary, carotid or peripheral artery revascularisation procedures~* Proliferative retinopathy requiring acute treatment or maculopathy (macular oedema) according to the Investigator's opinion~* Subjects with a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, endocrinological (except for the type 2 diabetes mellitus), neurological, genitourinary or haematological system that in the opinion of the Investigator may confound the results of the trial or pose additional risk in administering trial products~* History of chronic pancreatitis or idiopathic acute pancreatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin degludec/liraglutide + OADs (Type: EXPERIMENTAL): None
- Liraglutide or exenatide + OADs (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Severe acquired growth hormone deficiency~* No treatment with somatropin in the last 24 months before study participation~* Written informed consent~Exclusion Criteria:~* Contraindications for the treatment with somatropin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: None): None
- B (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ondansetron VS Doxylamine and Pyridoxine in Treating Nausea of Pregnancy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women who are less than 16 weeks pregnant by last menstrual period or ultrasound~* Greater than 18 years of age~* English speaking~* No significant visual or hearing impairment~* Requesting treatment for nausea associated with pregnancy~Exclusion Criteria:~* If nausea or vomiting preexisted the pregnancy~* Requires hospitalization at the time of initial enrollment~* Already taking anti-emetics to include metoclopramide, ondansetron, doxylamine, pyridoxine, or promethazine~* The patient has an allergy to either study regimen~* If they are unable to return for a follow up visit in 1 week

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Ondansetron (Type: EXPERIMENTAL): study drug
- Doxylamine and Pyridoxine (vitamin B6) (Type: NO_INTERVENTION): other nausea treatment in use

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study of an HIV Vaccine in Healthy, HIV Uninfected Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults (determined by medical history, physical examination, and clinical judgment)~* HIV uninfected~* Female participants of child bearing potential must have a negative serum β-human chorionic gonadotrophin pregnancy test at the screening visit and immediately prior to each vaccine/placebo administration, practice adequate birth control measures from 28 days prior to the first vaccine/placebo administration through to at least 3 months after the final vaccine/placebo administration~* Male participants who are sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a double barrier method of birth control, e.g. either condom with spermicidal foam/gel/film/cream/suppository or partner with occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/suppository~Exclusion Criteria:~* Confirmed HIV-1/-2 infection~* Chronic active hepatitis B or hepatitis C or active syphilis infection. Active syphilis documented by exam or serology unless positive serology is due to past treated infection~* Within the 12 months prior to enrollment: a history of newly acquired syphilis, gonorrhea, non-gonococcal urethritis, herpes simplex virus type 2 (HSV2), Chlamydia, pelvic inflammatory disease (PID), trichomonas, mucopurulent cervicitis, epididymitis, proctitis, lymphogranulomavenereum, chancroid, or hepatitis B~* A woman who is breastfeeding~* Any clinically significant acute or chronic medical condition that, in the opinion of the investigator, would preclude participation~* Major surgery within the 4 weeks prior to study entry or planned major surgery through the course of the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Group 1- MVA Mosaic (Type: EXPERIMENTAL): Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered Modified Vaccinia Ankara (MVA) Mosaic at Week 0 and at Week 12.
- Group 2 - Placebo (Type: PLACEBO_COMPARATOR): Healthy volunteers not previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.
- Group 3 - MVA Mosaic (Type: EXPERIMENTAL): Healthy volunteers previously vaccinated with Ad26.ENVA.01 will be administered MVA Mosaic at Week 0 and at Week 12.
- Group 4- Placebo (Type: PLACEBO_COMPARATOR): Participants previously vaccinated with Ad26.ENVA.01 will be administered placebo at Week 0 and at Week 12.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Enalapril Maleate on Arterial Stiffness in Rheumatoid Arthritis.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients classified with RA according to the American College of Rheumatology (ACR) / European League Against Rheumatism (EULAR) 2010~* Patients treated in the outpatient service of the Rheumatology Service of the Hospital Civil de Guadalajara Dr. Juan I Menchaca.~* Sign an Informed Consent Letter~* Under treatment with conventional Disease-Modifying Antirheumatic Drugs (DMARDS)~Exclusion Criteria:~* Patients with a previous diagnosis of diabetes mellitus, systemic hypertension, thyroid, kidney or liver disease~* History of acute myocardial infarction, cardiac arrhythmias, cerebral vascular event or heart failure~* Smoking active patients in the last 6 months~* Patients with a desire for close conception, pregnant or breastfeeding.~* Patients with blood pressure \<90/60 mmHg~* Patients who do not accept to participate in the study~* Patients with a BMI greater than ≥40 Kg / m2~* Non-palpable carotid and femoral pulses~* Unstable psychological state

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Enalapril Maleate (Type: EXPERIMENTAL): Enalapril Maleate 5 mg every 12 hrs for 90 days.
- Placebo (Type: EXPERIMENTAL): Substance that lacks in itself therapeutic action.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brief Interventions for Short-Term Suicide Risk Reduction in Military Populations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Active duty~* 18 years of age or older~* Reporting current suicidal ideation with intent to die, or a suicide attempt within the past two weeks~* Able to speak and understand the English language~* Able to complete the informed consent process~Exclusion Criteria:~* Severe psychiatric or medical conditions that preclude the ability to provide informed consent or participation in outpatient treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Treatment As Usual (TAU) (Type: ACTIVE_COMPARATOR): TAU includes the following intervention components:~1. suicide risk assessment~2. supportive listening~3. provision of professional and crisis contact information~4. referral to mental health treatment and community resources~5. verbal contract for safety
- Standard Crisis Response Plan (S-CRP) (Type: EXPERIMENTAL): CRP includes the following intervention components:~1. suicide risk assessment~2. supportive listening~3. identify personal warning signs~4. identify self-management skills~5. identify social support contacts~6. provision of professional and crisis contact information~7. referral to mental health treatment and community resources
- Enhanced Crisis Response Plan (E-CRP) (Type: EXPERIMENTAL): The E-CRP includes the following intervention components:~1. suicide risk assessment~2. supportive listening~3. identify personal warning signs~4. identify self-management skills~5. identify reasons for living~6. identify social support contacts~7. provision of professional and crisis contact information~8. referral to mental health treatment and community resources

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Psilocybin for Major Depressive Disorder (MDD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 21 to 65 years old~* Able to swallow capsules~* If of childbearing potential, agree to practice an effective means of birth control throughout the duration of the study~* Have an identified support person and agree to be accompanied home by that person following dosing~* Have sustained moderate-severe depression symptoms at Screening and Baseline~* Meet DSM-5 criteria for a diagnosis of major depressive disorder and are currently experiencing a major depressive episode of at least a 60-day duration at the time of screening~Exclusion Criteria:~* Women who are pregnant or who intend to become pregnant during the study or who are currently nursing~* Have any of the following cardiovascular conditions: uncontrolled hypertension, coronary artery disease, congenital long QT syndrome, cardiac hypertrophy, cardiac ischemia, congestive heart failure, myocardial infarction, tachycardia, artificial heart valve, a clinically significant screening ECG abnormality, or any other significant cardiovascular condition~* Have a history of stroke or Transient Ischemic Attack (TIA)~* Have moderate to severe hepatic impairment~* Have epilepsy~* Have insulin-dependent diabetes~* Have a positive urine drug test~* Nicotine dependence that would disallow an individual to be nicotine free for the 7-10 hours during the dosing period~* Meet DSM-5 criteria for schizophrenia spectrum or other psychotic disorders, including major depressive disorder with psychotic features, or Bipolar I or Bipolar II Disorder~* Meet DSM-5 criteria for antisocial personality disorder~* Meet DSM-5 criteria for a moderate or severe alcohol or drug use disorder

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Psilocybin (Type: EXPERIMENTAL): Participants will receive a single 25 mg dose of psilocybin along with the Set and Setting (SaS) protocol. Psilocybin is administered orally as a capsule and taken with water.
- Niacin (Type: ACTIVE_COMPARATOR): Participants will receive a single 100 mg dose of niacin along with the Set and Setting (SaS) protocol. Niacin is administered orally as a capsule and taken with water.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of HS based on clinical history and physical examination for at least 3 months.~* Diagnosis of HS (Hurley I or II) with the following:~  1. A total AN count of 3 to ≤ 10, with no draining tunnels at screening and baseline visits. AND~ 2. The AN count at the screening AND baseline visits:~* AN of 3 should affect at least 1 distinct anatomical area~* AN of \> 3 to ≤ 10 should affect at least 2 distinct anatomical areas.~* Baseline Skin Pain or Itch NRS score ≥ 1.~* Agreement to NOT use topical and systemic antibiotics for treatment of HS during the study.~* Agreement to NOT use a diluted beach bath or topical antiseptic washes containing chlorhexidine gluconate or benzoyl peroxide on the areas affected by HS lesions during the study.~* Willingness to avoid pregnancy or fathering children~Exclusion Criteria:~* Presence of draining tunnels at screening or at baseline visits.~* Concurrent conditions and history of other diseases:~  1. Active ongoing inflammatory diseases of the skin other than HS that might confound the evaluation of HS.~ 2. Any other concomitant skin disorder (eg, generalized erythroderma such as Netherton's syndrome), pigmentation, or extensive scarring that in the opinion of the investigator may interfere with the evaluation of HS AN or compromise participant safety.~ 3. Immunocompromised (eg, lymphoma, acquired immunodeficiency syndrome, or Wiskott-Aldrich syndrome).~ 4. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks before baseline.~ 5. Active acute bacterial, fungal, or viral skin infection (eg, herpes simplex, herpes zoster, chicken pox, clinically infected AD, or impetigo) within 2 weeks before baseline.~* Laboratory values outside of the protocol-defined criteria.~* Use of any prohibited medications per protocol-defined criteria.~* Pregnant or lactating participants, or those considering pregnancy during the period of their study participation.~* Other exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ruxolitinib Cream (Type: EXPERIMENTAL): Ruxolitinib 1.5% cream BID for 16 weeks of double-blind, vehicle-controlled (DBVC) period followed by ruxolitinb 1.5% cream BID for 16 weeks in an open-label extension.
- Vehicle Cream (Type: EXPERIMENTAL): Vehicle cream BID for 16 weeks of double-blind, vehicle-controlled (DBVC) period followed by ruxolitinb 1.5% cream BID for 16 weeks in an open-label extension.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare Oxymorphone Extended-Release (Opana ER) Versus Oxycodone Controlled-Release (Oxycontin)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Recreational opioid use.~* At least 3 lifetime occasions of recreational use of an oral intact modified-release opioid product.~* BMI within range of 19.0 to 29.9 kg/m2, inclusive, minimum weight of 50.0 kg at screening and Day 0 of treatment period 1~Exclusion Criteria:~* Self-reported history of drug or alcohol dependence in the past 2 years or presence of drug or alcohol dependence in the past 12 months as defined by the DSM-IV, including subjects who have ever been in a drug rehabilitation program.~* Unwillingness or inability to abstain from recreational drug use as required for the study.~* History of acute asthma or other obstructive airway disease or any condition that may increase the risk for respiratory depression, judged as clinically significant by the investigator or designee.~* History of neurologic conditions such as convulsive disorders or severe head injury, judged as clinically significant by the investigator or qualified designee.~* History of Addison's disease, hypothyroidism, pancreatitis, prostatic hypertrophy, or urethral stricture.~* Use of non-prescription or prescription medications or natural health products within 7 days prior to first drug administration in the qualification phase and throughout the study, unless in the opinion of the investigator or designee, the product will not interfere with the study procedures or data integrity or compromise the safety of the subject.~* Uses of Monoamine oxidize inhibitors (MAOIs) within 14 days of first drug administration in the qualification phase and throughout the study.~* Current consumption of greater than 20 cigarettes (or 2 cigars) per day or inability to abstain from smoking (or use of any nicotine-containing sub stance) for at least 14 hours.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Oxymorphone ER 15 mg (Type: EXPERIMENTAL): 15mg
- Oxycodone CR 30 mg (Type: ACTIVE_COMPARATOR): 30mg
- Placebo (Type: PLACEBO_COMPARATOR): None
- Oxymorphone ER 30mg (Type: EXPERIMENTAL): 30mg
- Oxycodone CR 60mg (Type: ACTIVE_COMPARATOR): 60mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cetrorelix Pamoate in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Benign Prostatic Hyperplasia, based on medical history~* Voiding symptoms~Exclusion Criteria:~* Urgent need for prostate surgery or prior surgical treatment of the prostate or bladder~* Major organ dysfunction~* Eczema (atopic dermatitis) treated during the last 6 months~* Current or recent treatment with sexual hormone drugs or 5 α reductase inhibitors or botulinum toxin type a (Botox) within the last 6 months prior randomization or with α blockers or saw palmetto within the last 6 weeks prior to randomization~* Urologic disorders including neurogenic bladder dysfunction due to diabetes mellitus or documented neurologic disorder, urethral stricture disease or history of pelvic radiation therapy~* History of acute obstructive, infectious, or neurological disorders of the genitourinary tract within the last 3 months

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetrorelix 78+78 (Type: EXPERIMENTAL): None
- Cetrorelix 78 + Placebo (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete